Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback